Animal models of scleroderma: Fresh insights

Current Opinion in Rheumatology

Volumn 22, Issue 6, 2010, Pages 677-682

  Artlett, Carol M ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

MSH; basic fibroblast growth factor; bleomycin; connective tissue growth factor; Egr 1; endothelin 1; HSC025; MCP 1; mouse model; NALP3 inflammasome; PPAR ; systemic sclerosis; vasculopathy

Indexed keywords

ALPHA INTERMEDIN; BASIC FIBROBLAST GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR; CRYOPYRIN; ENDOTHELIN 1; HERBACEOUS AGENT; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT MEDICINAL PRODUCT; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROSIGLITAZONE; TRANSCRIPTION FACTOR FLI 1; TRANSCRIPTION FACTOR FRA 2; TRANSFORMING GROWTH FACTOR BETA1; TRIHYDROXY ALPHA SANSHOOL; UNCLASSIFIED DRUG;

CELL PROLIFERATION; COMPETITIVE INHIBITION; CYTOKINE RELEASE; DISEASE MODEL; EMPHYSEMA; FIBROSIS; INNATE IMMUNITY; LUNG FIBROSIS; MEDICINAL PLANT; NONHUMAN; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; VASCULAR DISEASE; ZANTHOXYLUM PIPERITUM;

ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FIBROSIS; FOS-RELATED ANTIGEN-2; HUMANS; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEIN C-FLI-1; SCLERODERMA, SYSTEMIC;

EID: 77958061836     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833e307b     Document Type: Review

References (47)

1. Gruschwitz M, Muller PU, Sepp N, et al. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990; 94:197-203.
2. Gabrielli A, Di Loreto C, Taborro R, et al. Immunohistochemical localization of intracellular and extracellular associated TGF-beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993; 68:340-349.
3. Maurer B, Busch N,Jungel A, et al. Transcription factor Fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resemblinghuman systemic sclerosis. Circulation 2009; 120:2367-2376.
4. Asano Y, Stawski L, Hant F, et al. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010;176:1983-1998.
5. Richard V, Solans V, Favre J, et al. Role of endogenous endothelin in endothelial dysfunction in murine model of systemic sclerosis: tight skin mice 1. Fundam Clin Pharmacol 2008; 22:649-655.
6. Nakerakanti SS, Kapanadze B, Yamasaki M, et al. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006; 281:25259-25269.
7. Fleming JN, Nash RA, Mahoney WM Jr, Schwartz SM. Is scleroderma a vasculopathy? Curr Rheumatol Rep 2009; 11:103-110.
8. Asano Y, Markiewicz M, Kubo M, et al. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009; 29:425-434.
9. Abraham D, Dashwood M. Endothelin: role in vascular disease. Rheumatology 2008; 47 (Suppl 5):23-24.
10. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 2007; 5:45-52.
11. Marasciulo FL, Montagnani M, Potenza MA. Endothelin-1: the yin and yang on vascular function. Curr Med Chem 2006; 13:1655-1665.
12. Vancheeswaran R, MagoulasT, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fibrosis or vascular dysfunction? J Rheumatol 1994; 21:1838-1844.
13. Kawaguchi Y, Suzuki K, Hara M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53:506-510. (Pubitemid 24256979)
14. Rubin LJ, Badesch DB, Barst RJ, etal. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
15. Joglekar A, Tsai FS, McCloskey DA, et al. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006; 33:61-68.
16. Marie I, Beny JL. Endothelial dysfunction in murine model of systemic sclerosis: tight-skin mice 1. J Invest Dermatol 2002; 119:1379-1387.
17. Siracusa LD, McGrath R, MaQ, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996; 6:300-313.
18. Kapoor M, McCann M, Liu S, et al. Loss of peroxisome proliferator- activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009; 60:2822-2829.
19. Wu u, Melichian DS, Chang E, et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisomeprol iferator-activated receptor-gamma. Am J Pathol 2009; 174: 519-533.
20. Kokot A, Sindrilaru A, Schiller M, et al. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reducestissue fibrosis in a mouse model of scleroderma: melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis Rheum 2009; 60:592-603.
21. Chujo S, Shirasaki F, Kondo-Miyazaki M, et al. Role of connective tissue growth factor and its interaction with basic fibroblast growth factor andmacrophage chemoattractant protein-1 in skin fibrosis. J Cell Physiol2009; 220:189-195.
22. Wu U, Melichian DS, de la Garza M, et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol 2009; 175: 1041-1055.
23. Ghosh AK, Bhattacharyya S, Lakos G, etal. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004; 50:1305-1318.
24. BrzoskaT, LugerTA, MaaserC, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008; 29:581-602.
25. Colombo G, Buffa R, Bardella MT, et al. Anti-inflammatory effects of alpha-melanocyte-stimulating hormone in celiac intestinal mucosa. Neuroimmuno-modulation 2002; 10:208-216.
26. Bohm M, Raghunath M, Sunderkotter C, etal. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. J Biol Chem 2004; 279:6959-6966.
27. Hasegawa M, Matsushita Y, Horikawa M, et al. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mousemodels of systemic sclerosis. Arthritis Rheum 2009; 60:3465-3475.
28. Dooley S, Said HM, Gressner AM, et al. Y-box protein-1 is the crucial mediator of antifibrotic interferon-gamma effects. J Biol Chem 2006; 281:1784-1795.
29. Higashi K, Inagaki Y, Fujimori K, et al. Interferon-gamma interferes with transforming growth factor-beta signaling through direct interaction of YB-1 with Smad3. J Biol Chem 2003; 278:43470-43479.
30. Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Diff 2007; 14:10-22.
31. Martinon F. Detection of immune danger signals by NALP3. J Leukoc Biol 2008; 83:507-511.
32. Piccini A, Carta S, Tassi S, et al. ATP is released by monocytes stimulated with pathogen-sensing receptor ligands and induces IL-1b and IL-18 in an auto-crine way. Proc Natl Acad Sci \USA 2008; 105:8067-8072.
33. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006; 126:659-662.
34. Dinarello CA. A signal for the caspase-1 inflammasome free of TLR. Immunity 2008; 26:383-385.
35. Pirhonen J, Sareneva T, Kurimoto M, et al. Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J Immunol 1999; 162:7322-7329.
36. Andrei C, Margiocco P, Poggi A, et al. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci \USA 2004; 101:9745-9750.
37. Beretta L, Bertolotti F, Cappiello F, et al. Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung pathology. Hum Immunol 2007; 68:603-609.
38. \+ T cells, interleukin-1b, and tumor necrosis factor a in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005; 58:178-184.
39. Scala E, Pallotta S, Frezzolini A, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138:540-546.
40. Nakanishi K, YosjimotoT, Tsutsui H,OkamuraH. Interleukin-18 regulates both Th1 and Th2 responses. Ann Rev Immunol 2001; 19:423-474.
41. Cahill CM, Rogers JT. Interleukin-1b induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase dependent Akt/IkB kinase alpha pathway targeting activator protein-1. J Biol Chem 2008; 283:25900-25912.
42. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287:193-197.
43. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I: Overproduction of interleukin-6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992; 19:1207-1211.
44. Gasse P, Mary C, Guenon I, et al. IL-1R1/MyD88 signaling and the inflam-masome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007; 117:3786-3799.
45. Cassel SL, Eisenbarth SC, Lyer SS, et al. The NALP3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci USA 2008; 105:9035-9040.
46. Dostert C, Petrilli V, van Bruggen R, et al. Innate immune activation through NALP3 inflammasome sensing of asbestos and silica. Science 2008; 320:674-677.
47. Couillin I, Vasseur V, Charron S, et al. IL-1R1/MyD88 signaling is critical for elastase-induced lung inflammation and emphysema. J Immunol 2009;183:8195-8202.